Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Acadia Pharmaceuticals Inc.

ACAD

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Last trade $18.12
Day change -$0.555 (-2.97%)
Day range $17.95 – $19.26
Volume 638,826
Market cap $3.23B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.23B
Price / earnings
8.91×
Price / book
2.33×
Price / sales
2.68×
EV / sales
2.42×
EV / EBITDA
21.5×

Profitability

Earnings per share
$2.10
Return on assets
20.19%
Return on equity
26.11%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.82×
Quick ratio
3.7×
Cash ratio
0.97×

Cash flow

Price / cash flow
33.08×
Price / free cash flow
39.36×
Free cash flow
$81.99M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ACAD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$342.29M$307.96M$268.06M$283.99M$278.63M$264.57M$244.32M$259.6M
Cost of revenue$35.09M$28.32M$24.79M$26.23M$21.65M$20.73M$20.39M$21.8M
Gross profit$307.2M$279.64M$243.27M$257.76M$256.99M$243.83M$223.93M$237.8M
Selling, general and administrative$159.2M$160.25M$171.02M$155.62M$133.4M$133.51M$126.37M$130.08M
Research and development$76.28M$81.56M$76.87M$84.76M$87.83M$77.95M$78.27M$100.73M
Total operating expenses$235.48M$241.81M$247.89M$240.37M$221.23M$211.46M$204.64M$230.81M
Operating income$71.72M$37.84M-$4.62M$17.39M$35.76M$32.37M$19.29M$6.99M
Interest expense$8.42M$0$0$0$8.25M$0$0$0
Income before taxes$80.44M$46.47M$3.98M$26.32M$44.6M$40.21M$27.78M$161.09M
Income taxes$26.92M$14.97M$344K-$247.25M-$27.18M$13.55M$8.79M$17.34M
Net income$53.52M$31.5M$3.64M$273.57M$71.78M$26.67M$18.99M$143.74M
Net income attributable to common shareholders$53.52M$31.5M$3.64M$273.57M$71.78M$26.67M$18.99M$143.74M
EBITDA$80.82M$35.55M-$1.62M$20.32M$44.15M$29.87M$22.24M$12.2M
Basic earnings per share$0.31$0.18$0.02$1.61$0.43$0.16$0.11$0.86
Diluted earnings per share$0.31$0.18$0.02$1.58$0.42$0.16$0.11$0.86

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Viatris (VTRS) is expected to report Q3 2026 revenues of $3.78 billion and earnings of 64 cents per share, likely beating consensus estimates. The company faces headwinds from FDA import alerts affecting 11 products, supply disruptions, and competitive pressures, but these are expected to be offset by new product growth and strength in branded markets, particularly in Greater China and Emerging Markets.

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

Recursion Pharmaceuticals reported a Q3 loss of $0.22 per share, beating the consensus estimate of $0.24 loss, with an 8.33% earnings surprise. Revenue of $18.55 million surpassed estimates by 69.88%, up from $5.18 million year-over-year. The stock has underperformed the S&P 500 by 12.2% year-to-date and carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Acadia Pharmaceuticals is expected to report Q3 2026 earnings of $0.21 per share, representing a 19.2% year-over-year decline, despite revenues rising 20.2% to $334.87 million. With a negative Earnings ESP of -0.59% and Zacks Rank #3, the company is not considered a compelling earnings-beat candidate. However, Acadia has beaten consensus EPS estimates in 3 of the last 4 quarters, most recently delivering a +200% surprise.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Pomerantz LLP is investigating potential securities fraud claims against ACADIA Pharmaceuticals following disappointing Phase 3 trial results for remlifanserin announced on September 24, 2026. The drug narrowly missed its primary endpoint, causing ACAD stock to plummet 12.78% on the announcement day and an additional 6.76% the following day after analyst downgrades.

GlobeNewswire Inc.

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.